Navigation Links
Study shows increase of hip and knee replacements in the US
Date:4/14/2008

With the graying of Americas Baby Boomer generation, arthritis is a growing health concern. Traditionally associated with the elderly, this common joint disease currently afflicts over 20 million men and women in the United States. To aggravate matters, arthritis is also prevalent among the overweightwhich describes nearly 65 percent of our nations adult population. Fortunately, treating the pain and disability of arthritis has been revolutionized by surgical joint replacements of the hips and knees. Unfortunately, as hip and knee replacements have become a more popular option, the toll on Medicare, private insurers and hospitals has escalated. Despite its huge implications for the healthcare system, the projected impact of joint replacements has attracted scant study.

To assess and address this issue, Sunny Kim, PhD, a researcher with the Robert Stempel School of Public Health at Florida International University, started with one of the largest databases of hospital procedures available: the Nationwide Inpatient Sample (NIS). Using the latest revision of international procedure coding, Dr. Kim identified joint replacement cases throughout the US and analyzed increases in surgeries and costs between 1997 and 2004. The April 2008 issue of Arthritis Care & Research (www.interscience.wiley.com/journal/arthritis) presents hard-hitting numbers to back her conclusion: the burden resulting from hip/knee joint replacement is not only substantial but also increasing at a steep rate.

Among Dr. Kims significant, distressing findings:

  • In 2004, approximately 431,485 primary knee replacements were performeda 53 percent increase from the year 2000. 225,900 primary hip replacements were performed in the USmarking a 37 percent increase for the same period.

  • In 1997, about 60 of primary hip replacements
    '/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Robert J. Reilly, Joins Aethon Team, PITTSBURGH,...aethon.com ), the leading developer of mobile robo...nounced that Robert J. Reilly has,joined the compa...icer., Reilly, who was most recently Vice Preside...pecialty Pharmacy Division, brings more than 30,ye...
(Date:7/25/2008)...ce to be presented at Fenway Park ... /PRNewswire/ -- CVS/pharmacy announced today,that...llion in just 21 days,through its annual in-store ... seventh year of the annual fundraising effort whi...ALS research. This year,s fundraiser took,place in...
(Date:7/25/2008)...ng to drop pounds, study finds , , FRIDA...ded Monday morning weigh-ins knows this unalterabl...Now, researchers have some science to back up diet...: Most people do eat more on the weekend, even whe...ulgences can wreak havoc on weight control, either...
(Date:7/25/2008)...re an Olympian, Professional Athlete, Elite Amateu...ed to Know about Hydration to Boost Sports Perform... Marina del Rey, Calif. (V...are heading to Beijing following years of intense ...of capturing an Olympic medal and securing their p...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...tching some rays has been shown to boost vitamin D... the risk of disease. Higher sun exposure during c...a reduced risk of multiple sclerosis, according to...ucted a study in Tasmania, which is located at hig...
...w research shows women who allow only short interv...d risk for developing complications. Researchers i...en birth twice between 1992 and 1998. Results of t...t births are much more likely to become pregnant a...
Indians Stay Away from Coke, Pepsi After Toxin Scare
...ctors usually prescribe antibiotics for problems l...e drugs, especially penicillin, may also protect a...ia prevent a problem that involves the blockage of...s often occur when cholesterol plaques in blood ve...
Other Medicine News:
(Date:7/24/2008)...Support Prognostic Value of Circulating Tumor Cell...rnational, prospective,clinical trial found the nu... indicator of progression-free and overall surviva...ording to a report published in the July 1,issue o...onducted in the US, the Netherlands, and the Unite...
(Date:7/24/2008)...AIN VIEW, Calif., July 24 /...nounced today that it has initiated,its second Pha...ine).,AZ-004 is an inhalation product candidate be... in patients with schizophrenia or bipolar disorde...and rapid pharmacokinetic,(PK) properties resultin...
(Date:7/24/2008)...New JIT Enrollment Program Speeds Oncology Patient...ech, Inc., a Research Management,Organization (RMO...,companies to provide research and site management...-in-Time (JIT) enrollment strategy. The new,trials...ular Non-Hodgkin,s,Lymphoma, Metastatic Breast Can...
(Date:7/24/2008)...A ANTIPOLIS, France, July 24 /PRNewswire-FirstCall...ced the top-line results from the 52-week,open lab...he completion of,the 301 phase 3 study for naproxc...ndings and efficacy was maintained for the one-yea...ts, global assessment scale. In,addition, the resu...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 1Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 5Citrate appears to control buckyball clumping but environmental concerns remain 4478 1Citrate appears to control buckyball clumping but environmental concerns remain 4478 2Citrate appears to control buckyball clumping but environmental concerns remain 4478 3Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 1Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 2Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 3Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 1Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 2
...NGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM)...tion, may be an,effective treatment for moderate-t...going double-blind, placebo controlled Phase II,st...nduced good,clinical remissions and improved patie...researchers from Hebrew University-Hadassah,Medica...
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
Other Medicine Technology:Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3
Desmarrres Lid Retractor, round serrated handle, polished finish, overall length 130 mm.
The Storz Protege is an anterior segment unit only.
The CV-12000 provides the surgeon with all the options to perform today's newest techniques.
Phaco-emulsification systems CV series
Medicine Products: